Emergent BioSolutions (EBS) Misses Q1 EPS by 22c, Offers Guidance

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.13), $0.22 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $190.6 million versus the consensus estimate of $201.16 million.

GUIDANCE:

Emergent BioSolutions sees Q2 2019 revenue of $200-220 million, versus the consensus of $254.14 million.

Emergent BioSolutions sees FY2019 revenue of $1.06-1.14 billion, versus the consensus of $1.08 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Take-Two Interactive (TTWO) Reiterated at Buy by StoneX Ahead of November GTA VI Launch
• Yext, Inc. (YEXT) Tops Q2 EPS by 4c